# US 2008/0305178 A1 · Use of a high molecular weight extracellular haemoglobin as a blood substitute

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0305178 A1
- Document ID: US20080305178A1
- Status: Published application
- Kind: A1
- Application number: 12/110,936
- Filed: 2008-04-28
- Published: 2008-12-11
- Earliest claimed: 2000-05-31
- Assignees: Centre National De La Recherche Scientifique
- Inventors: Franck ZAL; Andre TOULMOND; Francois LALLIER
- Web page: https://patentgrep.com/patent/US20080305178A1

## CPC

- C07K 14/805: Haemoglobins; Myoglobins
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/08: Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04)
- C07K 14/43536: {from worms}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A blood substitute, of an extracellular haemoglobin having a molecular weight of approximately 3 to approximately 4 million daltons, comp sing chains of polymerised globins, containing free cysteines capable of binding to NO and/or SNO groups, and having a P50 of approximately 6 to approximately 7 mm Hg, and methods using the blood substitute.

## Claims

### Claim 1

A method for substituting blood comprising substituting said blood with an extracellular haemoglobin having a molecular weight of approximately 3 to approximately 4 million Daltons, comprising chains of polymerised globins, containing free cysteines binding to NO and/or SNO groups, and having a P50 of approximately 6 to approximately 7 mm Hg at 37° C.

### Claim 2

A blood substitute mixture comprising a physiologically acceptable buffer for a vertebrate and an extracellular haemoglobin as a blood substitute, said extracellular haemoglobin having a molecular weight of approximately 3 to approximately 4 million Daltons, comprising chains of polymerised globins, containing free cysteines binding to NO and/or SNO groups, and having a P50 of approximately 6 to approximately 7 mm Hg at 37° C.

### Claim 3 (depends on 2)

The blood substitute according to claim 2, wherein the haemoglobin cooperativity coefficient is 2 to 3 (n50).

### Claim 4 (depends on 2)

The blood substitute according to claim 2, wherein the globin chains of extracellular haemoglobin are stabilised between themselves, by covalent bonds, -and the globin chains are auto-stabilised by intramolecular disulphide bridges.

### Claim 5 (depends on 2)

The blood substitute according to claim 2, wherein the extracellular haemoglobin comprises structural chains which confer a hexagonal structure on the haemoglobin.

### Claim 6 (depends on 2)

The blood substitute according to claim 2, wherein the extracellular haemoglobin is capable of neutralising toxic compounds.

### Claim 7 (depends on 2)

The blood substitute according to claim 2, wherein the extracellular haemoglobin does not necessitate any cofactor to release any oxygen possibly fixed onto the haemoglobin.

### Claim 8 (depends on 2)

The blood substitute according to claim 2, wherein the extracellular haemoglobin possesses the following properties:
the extracellular haemoglobin is non-toxic
the extracellular haemoglobin has no pathogenic agent
the extracellular haemoglobin keeps for at least 6 weeks at 4° C. without oxidation
the extracellular haemoglobin is transfusable into all blood types
the extracellular haemoglobin has a sufficiently long residence time to ensure regeneration into natural haemoglobin of the organism into which the extracellular haemoglobin is transfused
the extracellular haemoglobin is eliminated by the organism into which the extracellular haemoglobin is transfused without side effects.

### Claim 9 (depends on 2)

The blood substitute according to claim 2, wherein the extracellular haemoglobin comes from Annelids.

### Claim 10 (depends on 9)

The blood substitute according to claim 9, wherein the extracellular haemoglobin comes from Arenicola marina.

### Claim 11 (depends on 2)

The blood substitute according to claim 2, wherein the blood substitute is a human blood substitute.

### Claim 12 (depends on 4)

The blood substitute according to claim 4, wherein the covalent bonds are intermolecular disulphide bridges.

### Claim 13 (depends on 6)

The method according to claim 6, wherein the toxic compound is a hydrogen sulphide.

### Claim 14

A method for administering a blood substitute mixture to a human, comprising administering to said human an effective concentration level of an extracellular haemoglobin, and wherein said extracellular haemoglobin has a molecular weight of approximately 3 to approximately 4 million Daltons, comprising chains of polymerised globins, containing free cysteines binding to NO and/or SNO groups, and having a P50 of approximately 6 to approximately 7 mm Hg at 37° C.

### Claim 15 (depends on 14)

The method according to claim 14, wherein said extracellular haemoglobin is obtained from Arenicola marina.

### Claim 16 (depends on 1)

The method according to claim 1, wherein said extracellular haemoglobin is obtained from Arenicola marina.

### Claim 17

A blood substitute comprising plasma and an extracellular haemoglobin having a molecular weight of approximately 3 to approximately 4 million Daltons, comprising chains of polymerised globins, containing free cysteines binding to NO and/or SNO groups, and having a P50 of approximately 6 to approximately 7 mm Hg at 37° C.

### Claim 18

A method for substituting blood comprising substituting said blood with a mixture comprising a physiologically acceptable buffer for a vertebrate and an extracellular haemoglobin as a blood substitute, said extracellular haemoglobin having a molecular weight of approximately 3 to approximately 4 million Daltons, comprising chains of polymerized globins, containing free cysteines binding to NO and/or SNO groups, and having a P50 of approximately 6 to approximately 7 mm at 37° C.

### Claim 19 (depends on 14)

The method according to claim 14, comprising administering to said human an effective concentration level of an appropriate buffer and an extracellular haemoglobin.

### Claim 20 (depends on 2)

The blood substitute mixture of claim 2, wherein said buffer comprises Hepes.

### Claim 21 (depends on 18)

The method of claim 18, wherein said buffer comprises Hepes.

### Claim 22 (depends on 19)

The method of claim 19, wherein said buffer comprises Hepes.

### Claim 23 (depends on 2)

The blood substitute according to claim 2, wherein the extracellular haemoglobin exhibits a SOD activity of 10 U/mg of protein.

### Claim 24 (depends on 2)

The blood substitute according to claim 2, wherein the extracellular haemoglobin in non immunogenic.
